Metformin and Chemoprevention: Potential for Heart-Healthy Targeting of Biologically Aggressive Breast Cancer.

Frontiers in Public Health
Veronica C JonesVictoria L Seewaldt

Abstract

Currently, tamoxifen is the only drug approved for reduction of breast cancer risk in premenopausal women. The significant cardiovascular side effects of tamoxifen, coupled with lack of a survival benefit, potential for genotoxicity, and failure to provide a significant risk-reduction for estrogen receptor-negative breast cancer, all contribute to the low acceptance of tamoxifen chemoprevention in premenopausal women at high-risk for breast cancer. While other prevention options exist for postmenopausal women, there is a search for well-tolerated prevention agents that can simultaneously reduce risk of breast cancers, cardiovascular disease, and type-2 diabetes. Metformin is a well-tolerated oral biguanide hypoglycemic agent that is prescribed worldwide to over 120 million individuals with type-2 diabetes. Metformin is inexpensive, safe during pregnancy, and the combination of metformin, healthy lifestyle, and exercise has been shown to be effective in preventing diabetes. There is a growing awareness that prevention drugs and interventions should make the "whole woman healthy." To this end, current efforts have focused on finding low toxicity alternatives, particularly repurposed drugs for chemoprevention of breast cancer, inc...Continue Reading

References

Feb 8, 2002·The New England Journal of Medicine·William C KnowlerUNKNOWN Diabetes Prevention Program Research Group
Mar 22, 2002·The Breast Journal·C J Fabian, B F Kimler
Jun 7, 2006·JAMA : the Journal of the American Medical Association·Victor G VogelUNKNOWN National Surgical Adjuvant Breast and Bowel Project (NSABP)
Sep 6, 2006·Gastroenterology·David Grahame Hardie
Feb 22, 2007·Journal of the National Cancer Institute·Jack CuzickUNKNOWN International Breast Cancer Intervention Study I Investigators
Feb 22, 2007·Journal of the National Cancer Institute·Trevor J PowlesMitch Dowsett
May 2, 2007·Journal of the National Cancer Institute·Umberto VeronesiUNKNOWN Italian Tamoxifen Study Group
May 4, 2007·The Journal of Clinical Investigation·Yan ShuKathleen M Giacomini
Jun 21, 2007·Breast Cancer Research and Treatment·Robert C MillikanCharles M Perou
Jul 5, 2007·Clinical Pharmacology and Therapeutics·Y ShuK M Giacomini
Oct 2, 2008·The Journal of Clinical Endocrinology and Metabolism·Robert E RatnerUNKNOWN Diabetes Prevention Program Research Group
Dec 17, 2008·Clinical Breast Cancer·Pamela J GoodwinI George Fantus
Jan 10, 2009·Seminars in Cancer Biology·R Brooks Robey, Nissim Hay
Jul 28, 2010·The Journal of Clinical Endocrinology and Metabolism·Alessandra GambineriRenato Pasquali
Dec 28, 2010·Nature Genetics·UNKNOWN GoDARTS and UKPDS Diabetes Pharmacogenetics Study GroupEwan R Pearson
Jan 19, 2011·Clinical Pharmacokinetics·Garry G GrahamKenneth M Williams
May 28, 2011·Diabetes Care·Kasia J LipskaSilvio E Inzucchi
Jun 7, 2011·The New England Journal of Medicine·Paul E GossUNKNOWN NCIC CTG MAP.3 Study Investigators
Oct 1, 2011·Clinical Pharmacology and Therapeutics·J H ChoiK M Giacomini
Dec 14, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Debora MacisAndrea Decensi
Mar 8, 2012·Journal of the National Cancer Institute·Meredith M ReganUNKNOWN Breast International Group (BIG) 1-98 Collaborative Group
May 9, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bernardo BonanniAndrea Decensi
May 9, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kevin Kalinsky, Dawn L Hershman
Jun 23, 2012·Pharmacogenetics and Genomics·Li GongTeri E Klein
Aug 31, 2012·Breast Cancer Research and Treatment·Saroj NiraulaPamela J Goodwin
Dec 27, 2012·Clinical Pharmacology and Therapeutics·S L StockerK M Giacomini

❮ Previous
Next ❯

Citations

Apr 16, 2021·European Journal of Medicinal Chemistry·Deepika KathuriaPrasad V Bharatam
Aug 8, 2021·European Journal of Medicinal Chemistry·Oleksandr GrytsaiRachid Benhida
Aug 28, 2021·Biomolecules·Cecilia MariniGianmario Sambuceti

❮ Previous
Next ❯

Methods Mentioned

BETA
xenograft
biopsy

Clinical Trials Mentioned

NCT00897884
NCT00909506
NCT00930579
NCT00933309
NCT01042379
NCT01101438
NCT01310231
NCT01650506
NCT01980823
NCT02145559

Software Mentioned

METALLICA

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Mammary Gland Biology and Neoplasia
J FariaF Martel
Current Problems in Cancer
Anindita De, Gowthamarajan Kuppusamy
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology
Massimiliano CazzanigaA Decensi
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology
Jaclyn Lee Fong BoscoTimothy L Lash
© 2021 Meta ULC. All rights reserved